Assessing Toripalimab in NSCLC.

According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non-small cell lung cancer lacking actionable mutations. The findings boost combination chemo-immunotherapy, rather than chemotherapy alone, as the new standard for this population.